They sure don't make it easy to follow along. M
Post# of 148054
(Total Views: 483)
Posted On: 11/03/2021 4:27:28 PM
They sure don't make it easy to follow along.
My reading comprehension was poor, and on review,I think the 3600% survival numbers must come from OS12, or overall survival at 12 months, not mOS.
Apparently mOS is around 6 months for mTNBC, so there is no way we are improved 35x or decades for mOS.
https://www.sec.gov/Archives/edgar/data/11756...dex992.htm
Is the closest we got to numbers explaining the PRs on mTNBC in trial, compassionate use, and basket trial.
Slide 11 summary says "Decrease in CAMLs after leronlimab induction were seen in 72% of patients which were associated with a significant 450% increase in overall survival at 12 months." That was for 21/29 patients (72%) with decreases in CAMLs at 30 days. It looked like 14/21 survived (67%), whereas SOC would expect only say 10%? Now including the 3 with low CTCs to start, maybe 17/21 are still alive at 12 months (81%), whereas maybe only 2-3% are expected (why the change?)? It's the only way I can figure how we get to "3600% improvement" in survival (at 12 months).
My reading comprehension was poor, and on review,I think the 3600% survival numbers must come from OS12, or overall survival at 12 months, not mOS.
Apparently mOS is around 6 months for mTNBC, so there is no way we are improved 35x or decades for mOS.
https://www.sec.gov/Archives/edgar/data/11756...dex992.htm
Is the closest we got to numbers explaining the PRs on mTNBC in trial, compassionate use, and basket trial.
Slide 11 summary says "Decrease in CAMLs after leronlimab induction were seen in 72% of patients which were associated with a significant 450% increase in overall survival at 12 months." That was for 21/29 patients (72%) with decreases in CAMLs at 30 days. It looked like 14/21 survived (67%), whereas SOC would expect only say 10%? Now including the 3 with low CTCs to start, maybe 17/21 are still alive at 12 months (81%), whereas maybe only 2-3% are expected (why the change?)? It's the only way I can figure how we get to "3600% improvement" in survival (at 12 months).
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼